4/A: Pacira BioSciences Amends Director's RSU Grant

Pacira BioSciences, Inc. filed an amended Form 4 to correct the number of restricted stock units granted to Director Mark A. Kronenfeld.

Summary

• Pacira BioSciences, Inc. (PCRX) filed a Form 4/A, an amendment to a previously filed Statement of Changes in Beneficial Ownership.
• The amendment corrects an inadvertent error in the original Form 4 regarding a grant of restricted stock units (RSUs) to Director Mark A. Kronenfeld.
• The original filing incorrectly reported a grant of 9,999 RSUs.
• The corrected amount of restricted stock units granted is 6,163.
• These 6,163 restricted stock units were granted on June 11, 2025, at a price of $0 per unit.
• Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
• The RSUs are scheduled to vest on June 11, 2026, contingent upon Mr. Kronenfeld's continuous service with the issuer through that date.
• Following this transaction, Mark A. Kronenfeld directly beneficially owns 31,065 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine administrative correction of an insider transaction, which does not indicate any material positive or negative operational or financial developments for the company.

Future Outlook

This filing does not contain forward-looking statements or guidance beyond the vesting schedule of the restricted stock units.

Industry Context

StockSavvy.ai notes that Form 4/A filings are routine amendments to correct administrative errors in insider transaction reports and typically do not reflect broader industry trends or competitive shifts. They are primarily for regulatory compliance and transparency regarding executive compensation.

Stakeholder Impact

• Shareholders: Provides corrected information regarding director compensation, enhancing transparency.

Key Dates

Recommendation

This filing is an administrative correction of an insider RSU grant and does not provide new material information that would warrant a change in investment recommendation. The core business fundamentals and outlook remain unchanged based on this amendment.

Keywords

Pacira BioSciences, PCRX, Form 4/A, SEC filing, restricted stock units, RSU grant, insider transaction, beneficial ownership, corporate governance